AEACEI
MCID: ANG049
MIFTS: 34

Angioedema Induced by Ace Inhibitors (AEACEI) malady

Categories: Genetic diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioedema Induced by Ace Inhibitors

Aliases & Descriptions for Angioedema Induced by Ace Inhibitors:

Name: Angioedema Induced by Ace Inhibitors 54 66
Angioedema Induced by Ace Inhibitors, Susceptibility to 54 29
Acquired Angioedema 56 69
Renin-Angiotensin-Aldosterone System-Blocker-Induced Angioneurotic Edema 56
Renin-Angiotensin-Aldosterone System-Blocker-Induced Angioedema 56
Drug-Related Side Effects and Adverse Reactions 42
Acquired Non Histamine-Induced Angioedema 56
Raas-Blocker-Induced Angioneurotic Edema 56
Acquired Bradykinine-Induced Angioedema 56
Acquired C1 Inhibitor Deficiency 56
Raas-Blocker-Induced Angioedema 56
Acquired Angioneurotic Edema 56
Ae-Acei 66
Aeacei 66
Rae 56
Aae 56

Characteristics:

Orphanet epidemiological data:

56
acquired angioedema
Inheritance: Not applicable; Age of onset: Adult;
renin-angiotensin-aldosterone system-blocker-induced angioedema
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult;

Classifications:



External Ids:

OMIM 54 300909
ICD10 via Orphanet 34 T78.3
MESH via Orphanet 43 C538173
UMLS via Orphanet 70 C2931758
MedGen 40 CN069588

Summaries for Angioedema Induced by Ace Inhibitors

OMIM : 54 Approximately 40 million people take ACE inhibitors (ACEi) to treat hypertension and cardiovascular disease. A small... (300909) more...

MalaCards based summary : Angioedema Induced by Ace Inhibitors, also known as angioedema induced by ace inhibitors, susceptibility to, is related to acquired angioedema and acquired angioedema type 2, and has symptoms including angioedema, edema and abdominal pain. An important gene associated with Angioedema Induced by Ace Inhibitors is XPNPEP2 (X-Prolyl Aminopeptidase 2). The drugs Ceftazidime and Benazepril have been mentioned in the context of this disorder. Affiliated tissues include tongue and bone.

UniProtKB/Swiss-Prot : 66 Angioedema induced by ACE inhibitors: A potentially life-threatening side effect of ACE inhibitors that appears in a subset of patients taking these drugs for hypertension and cardiovascular disease treatment. AEACEI is characterized by swelling of the face, lips, tongue, and airway that can lead to suffocation and death if severe.

Related Diseases for Angioedema Induced by Ace Inhibitors

Diseases related to Angioedema Induced by Ace Inhibitors via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 acquired angioedema 12.4
2 acquired angioedema type 2 12.1
3 acquired angioedema type 1 12.0
4 angioedema, hereditary, types i and ii 11.2
5 reactive angioendotheliomatosis 10.8
6 angioedema 10.0
7 neuronitis 9.9

Graphical network of the top 20 diseases related to Angioedema Induced by Ace Inhibitors:



Diseases related to Angioedema Induced by Ace Inhibitors

Symptoms & Phenotypes for Angioedema Induced by Ace Inhibitors

Clinical features from OMIM:

300909

Human phenotypes related to Angioedema Induced by Ace Inhibitors:

56 32 (show all 9)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 angioedema 56 32 Very frequent (99-80%) HP:0100665
2 edema 56 Very frequent (99-80%)
3 abdominal pain 56 Very frequent (99-80%)
4 ascites 56 Occasional (29-5%)
5 intestinal obstruction 56 Occasional (29-5%)
6 urticaria 56 Occasional (29-5%)
7 facial edema 56 Occasional (29-5%)
8 intestinal edema 56 Occasional (29-5%)
9 laryngeal edema 56 Occasional (29-5%)

Drugs & Therapeutics for Angioedema Induced by Ace Inhibitors

Drugs for Angioedema Induced by Ace Inhibitors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1123)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftazidime Approved Phase 4 78439-06-2 5481173
2
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
3
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
4
Enalapril Approved, Vet_approved Phase 4,Phase 3 75847-73-3 5362032 40466924
5
Enalaprilat Approved Phase 4,Phase 3 76420-72-9 6917719
6
Eprosartan Approved Phase 4 133040-01-4 5281037
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 437-38-7 3345
8
Fosinopril Approved Phase 4 98048-97-6 55891
9
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
10
Lisinopril Approved, Investigational Phase 4,Phase 2 83915-83-7 5362119
11
Losartan Approved Phase 4,Phase 3 114798-26-4 3961
12
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
13
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 158781 130881
14
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
15
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
16
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
17
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
18
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
19
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
20
Trandolapril Approved Phase 4 87679-37-6 5484727
21
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
22
Desflurane Approved Phase 4 57041-67-5 42113
23
Etomidate Approved Phase 4 33125-97-2 36339 667484
24
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
25
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 2078-54-8 4943
26
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
27
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
28
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2 3056-17-5 18283
29
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
30
Hydralazine Approved Phase 4 86-54-4 3637
31
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
32
Citalopram Approved Phase 4,Phase 3,Early Phase 1 59729-33-8 2771
33
Magnesium Sulfate Approved, Vet_approved Phase 4 7487-88-9 24083
34
Teicoplanin Approved Phase 4 61036-62-2
35
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
36
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
37
Bupivacaine Approved, Investigational Phase 4,Phase 2 2180-92-9, 38396-39-3 2474
38
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 1,Phase 2 128-13-2 31401
39
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
40
Methylphenidate Approved, Investigational Phase 4,Phase 2 113-45-1 4158
41
Adalimumab Approved Phase 4 331731-18-1 16219006
42
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
43
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
44
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
45
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
46
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
47
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
48
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 1,Phase 2 128794-94-5 5281078
49
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
50
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 104987-11-3 445643 439492

Interventional clinical trials:

(show top 50) (show all 1535)
id Name Status NCT ID Phase
1 Adverse Drug Reactions of Different Brands of Ceftazidime Injection Unknown status NCT00173901 Phase 4
2 ACEIs and ARBs Treatment in Diabetic Patients -Drug Interactions and Adverse Drug Effects Unknown status NCT00437775 Phase 4
3 Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics Unknown status NCT01715584 Phase 4
4 Explore Active Surveillance Mode of the Community's Adverse Event Following Immunization(AEFI) Unknown status NCT01830257 Phase 4
5 The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting Unknown status NCT02213718 Phase 4
6 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
7 Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4
8 The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients Unknown status NCT01041963 Phase 4
9 Prevention of Potentially Inappropriate Prescribing in Late Life Using Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) and Screening Tool to Alert Doctors to Right Treatment (START) Criteria Unknown status NCT00915824 Phase 4
10 The Angiotensin Converting Enzyme (ACE) Inhibitor SwitchBack Study Unknown status NCT01162980 Phase 4
11 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4
12 Magnesium Sulphate and Sevoflurane Induced Emergence Agitation in Children Unknown status NCT01743144 Phase 4
13 A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely Unknown status NCT00368498 Phase 4
14 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4
15 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4
16 The Use of Iron Therapy for Patients With Anemia After Surgery Unknown status NCT01975272 Phase 4
17 A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes Unknown status NCT00144144 Phase 4
18 Dose Finding Study for Continuous Spinal Anaesthesia Unknown status NCT01680120 Phase 4
19 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4
20 Attention Deficit Disorder Medication Response Study Unknown status NCT01727414 Phase 4
21 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
22 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4
23 Pharmaceutical Care of Patients With Impaired Mobility in a Model-region of Decreasing Supply of Medical Services Unknown status NCT01587599 Phase 4
24 Collection, Evaluation and Assessment of Adverse Drug Reactions on the Oncology Ward Completed NCT01058122 Phase 4
25 Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Completed NCT01467050 Phase 4
26 Adverse Drug Event Prevention Using Structured Pharmacist Review Completed NCT01467128 Phase 4
27 CYP4A11 and CYP4F2 Gene Variants as Makers of Cardiovascular Adverse Events of Non-steroidal Anti-inflammatory Drugs Completed NCT02779530 Phase 4
28 Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose Completed NCT02811185 Phase 4
29 Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants Completed NCT02720328 Phase 4
30 A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women Completed NCT01354730 Phase 4
31 Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin Completed NCT01775839 Phase 4
32 Echinacea Safety Study Completed NCT01021995 Phase 4
33 Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients Completed NCT00823966 Phase 4
34 Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study Completed NCT01679964 Phase 4
35 Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan Completed NCT01412398 Phase 4
36 Standardized Educational Plan for Epilepsy Patients With Comorbidities Completed NCT01804322 Phase 4
37 Post Marketing Surveillance Study on Emselex After Launch in Germany Completed NCT00786448 Phase 4
38 The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in Children Completed NCT00550160 Phase 4
39 Aminotransferase Trends During Prolonged Acetaminophen Dosing Completed NCT00743093 Phase 4
40 Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients. Completed NCT00337493 Phase 4
41 Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients Completed NCT00135551 Phase 4
42 Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section Completed NCT02044549 Phase 4
43 Switching Medication to Treat Schizophrenia Completed NCT00044655 Phase 4
44 Drug Use Investigation Of Gabapentin Completed NCT00567268 Phase 4
45 Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis Completed NCT02551536 Phase 4
46 Sub-dissociative Ketamine for the Management of Acute Pediatric Pain Completed NCT01951963 Phase 4
47 S.L. Spray Solution® and Difflam® and Acular®Spray for the Prevention of Postoperative Sore Throat Completed NCT02608788 Phase 4
48 Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department Completed NCT02916927 Phase 4
49 Treatment of Smoking Lapses and Relapses Completed NCT01807871 Phase 4
50 A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4

Search NIH Clinical Center for Angioedema Induced by Ace Inhibitors

Cochrane evidence based reviews: drug-related side effects and adverse reactions

Genetic Tests for Angioedema Induced by Ace Inhibitors

Genetic tests related to Angioedema Induced by Ace Inhibitors:

id Genetic test Affiliating Genes
1 Angioedema Induced by Ace Inhibitors, Susceptibility to 29

Anatomical Context for Angioedema Induced by Ace Inhibitors

MalaCards organs/tissues related to Angioedema Induced by Ace Inhibitors:

39
Tongue, Bone

Publications for Angioedema Induced by Ace Inhibitors

Articles related to Angioedema Induced by Ace Inhibitors:

id Title Authors Year
1
Acute abdomen due to intestinal angioedema induced by ACE inhibitors: not so rare? ( 20163043 )
2009
2
[Angioedema induced by ACE inhibitors and angiotensin II-receptor antagonists: analysis of 98 cases]. ( 10198947 )
1999

Variations for Angioedema Induced by Ace Inhibitors

ClinVar genetic disease variations for Angioedema Induced by Ace Inhibitors:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 XPNPEP2 NG_011479.1: g.2846C> A single nucleotide variant risk factor rs3788853 GRCh37 Chromosome X, 128870791: 128870791

Expression for Angioedema Induced by Ace Inhibitors

Search GEO for disease gene expression data for Angioedema Induced by Ace Inhibitors.

Pathways for Angioedema Induced by Ace Inhibitors

GO Terms for Angioedema Induced by Ace Inhibitors

Sources for Angioedema Induced by Ace Inhibitors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....